# Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study)

> **NCT01082510** · PHASE3 · UNKNOWN · sponsor: **Urological Oncology Council of Northern Tokyo** · enrollment: 288 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Bacille Calmette-Guerin
- **DRUG:** uracil-tegafur

## Key facts

- **NCT ID:** NCT01082510
- **Lead sponsor:** Urological Oncology Council of Northern Tokyo
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-01
- **Primary completion:** 2017-12
- **Final completion:** 2019-12
- **Target enrollment:** 288 (ESTIMATED)
- **Last updated:** 2011-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01082510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01082510, "Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01082510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*